• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国 1973-2005 年输尿管和肾盂癌患者的发病率和生存率。

Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005.

机构信息

Division of Urology, Department of Surgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.

出版信息

BJU Int. 2011 Apr;107(7):1059-64. doi: 10.1111/j.1464-410X.2010.09675.x. Epub 2010 Sep 3.

DOI:10.1111/j.1464-410X.2010.09675.x
PMID:20825397
Abstract

OBJECTIVE

• To evaluate epidemiological and survival patterns of upper-tract urothelial carcinoma (UTUC) over the past 30 years through a review of a large, population-based database.

PATIENTS AND METHODS

• Data from the Surveillance, Epidemiology and End Results (SEER) database from 1973 to 2005 were reviewed in 10-year increments to evaluate disease trends. • Univariate and multivariate survival analyses identified prognostic variables for outcomes.

RESULTS

•In total, 13,800 SEER-registered cases of UTUC were included. The overall incidence of UTUC increased from 1.88 to 2.06 cases per 100,000 person-years during the period studied, with an associated increase in ureteral disease (0.69 to 0.91) and a decrease in renal pelvic cancers (1.19 to 1.15). • The proportion of in situ tumours increased from 7.2% to 31.0% (P < 0.001), whereas local tumours declined from 50.4% to 23.6% (P < 0.001). • There was no change in the proportion of patients presenting with distant disease. • In multivariate analysis, increasing patient age (P < 0.001), male gender (P < 0.001), black non-Hispanic race (P < 0.001), bilateral UTUC (P = 0.001) and regional/distant disease (P < 0.001) were all associated with poorer survival outcomes.

CONCLUSIONS

• The incidence of UTUC has slowly risen over the past 30 years. • Increased use of bladder cancer surveillance regimens and improved abdominal cross-sectional imaging may contribute to the observed stage migration towards more in situ lesions. • Although pathological disease characteristics impact cancer outcomes, certain sociodemographic factors also appear to portend worse prognosis.

摘要

目的

通过回顾大型基于人群的数据库,评估过去 30 年来上尿路尿路上皮癌 (UTUC) 的流行病学和生存模式。

患者和方法

回顾 1973 年至 2005 年期间监测、流行病学和最终结果 (SEER) 数据库中的数据,每 10 年评估一次疾病趋势。单变量和多变量生存分析确定了预后变量。

结果

共纳入了 13800 例 SEER 登记的 UTUC 病例。UTUC 的总发病率从研究期间的每 100,000 人年 1.88 例增加到 2.06 例,输尿管疾病(从 0.69 增加到 0.91)增加,肾盂癌(从 1.19 减少到 1.15)减少。原位肿瘤的比例从 7.2%增加到 31.0%(P <0.001),而局部肿瘤的比例从 50.4%下降到 23.6%(P <0.001)。远处疾病患者的比例没有变化。多变量分析显示,患者年龄增加(P <0.001)、男性(P <0.001)、黑人非西班牙裔(P <0.001)、双侧 UTUC(P=0.001)和区域/远处疾病(P <0.001)与生存结局较差相关。

结论

过去 30 年来,UTUC 的发病率缓慢上升。膀胱癌监测方案的使用增加和腹部横断面成像的改善可能导致观察到的向更原位病变的分期迁移。尽管病理疾病特征影响癌症结局,但某些社会人口因素似乎也预示着预后更差。

相似文献

1
Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005.美国 1973-2005 年输尿管和肾盂癌患者的发病率和生存率。
BJU Int. 2011 Apr;107(7):1059-64. doi: 10.1111/j.1464-410X.2010.09675.x. Epub 2010 Sep 3.
2
Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients.肾输尿管切除术和节段性输尿管切除术治疗浸润性上尿路尿路上皮癌:2299 例患者的基于人群研究。
Eur J Cancer. 2009 Dec;45(18):3291-7. doi: 10.1016/j.ejca.2009.06.016. Epub 2009 Jul 15.
3
Transitional cell carcinomas of the renal pelvis and the ureter: comparative demographic characteristics, pathological grade and stage and 5-year survival in a Taiwanese population.肾盂和输尿管移行细胞癌:台湾人群的比较人口统计学特征、病理分级和分期以及5年生存率
BJU Int. 2009 Feb;103(3):312-6. doi: 10.1111/j.1464-410X.2008.07985.x. Epub 2008 Sep 8.
4
Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma.原发性肿瘤的位置并非上尿路尿路上皮癌患者癌症特异性死亡率的独立预测因素。
J Urol. 2009 Nov;182(5):2177-81. doi: 10.1016/j.juro.2009.07.035. Epub 2009 Sep 16.
5
[A clinicopathological evaluation of prognostic factors of urothelial tumors of the renal pelvis and ureter].[肾盂及输尿管尿路上皮肿瘤预后因素的临床病理评估]
Hinyokika Kiyo. 2001 Apr;47(4):237-40.
6
Effect of age on transitional cell carcinoma of the upper urinary tract: presentation, treatment, and outcomes.年龄对上尿路移行细胞癌的影响:表现、治疗和结果。
Urology. 2011 Jul;78(1):87-92. doi: 10.1016/j.urology.2011.03.032. Epub 2011 May 23.
7
[A clinical study on transitional cell carcinoma of renal pelvis and ureter].[肾盂及输尿管移行细胞癌的临床研究]
Hinyokika Kiyo. 1993 Aug;39(8):701-4.
8
Squamous cell carcinoma of the renal pelvis and ureter: incidence, symptoms, treatment and outcome.肾盂和输尿管鳞状细胞癌:发病率、症状、治疗及预后
J Urol. 2007 Jul;178(1):51-6. doi: 10.1016/j.juro.2007.03.033. Epub 2007 May 11.
9
[The expression of p53 and c-erb-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival].[肾盂及输尿管移行细胞癌中p53和c-erb-2的表达及其与肿瘤进展和生存的关系]
Arch Esp Urol. 2002 Sep;55(7):792-6.
10
Upper tract urothelial neoplasms: incidence and survival during the last 2 decades.上尿路尿路上皮肿瘤:过去20年的发病率和生存率
J Urol. 2000 Nov;164(5):1523-5.

引用本文的文献

1
A rare case of primary invasive urothelial carcinoma of the renal pelvis and calyx: a case report.肾盂和肾盏原发性浸润性尿路上皮癌1例:病例报告
Ecancermedicalscience. 2025 Jun 20;19:1928. doi: 10.3332/ecancer.2025.1928. eCollection 2025.
2
Diagnostic accuracy of urinary PENK methylation test for urothelial and other cancers: A prospective study.尿PENK甲基化检测对尿路上皮癌及其他癌症的诊断准确性:一项前瞻性研究。
Sci Rep. 2025 Jul 1;15(1):22149. doi: 10.1038/s41598-025-07173-5.
3
Uncovering the Risk: Incidence of Upper Tract Urothelial Carcinoma Following Renal Transplantation in the Netherlands.
揭示风险:荷兰肾移植术后上尿路尿路上皮癌的发病率
Eur Urol Open Sci. 2025 Apr 16;76:1-6. doi: 10.1016/j.euros.2025.03.004. eCollection 2025 Jun.
4
A Nomogram to Predict Cancer-Specific Survival of Transitional Cell Carcinoma of Ureter After Surgery.预测输尿管移行细胞癌术后癌症特异性生存的列线图
Medicina (Kaunas). 2025 Jun 9;61(6):1062. doi: 10.3390/medicina61061062.
5
Improving Urothelial Carcinoma Outcomes: The Powerful Combination of Neoadjuvant and Adjuvant Chemotherapy in the Perioperative Period.改善尿路上皮癌的治疗效果:围手术期新辅助化疗与辅助化疗的强效联合
Ann Surg Oncol. 2025 Mar 27. doi: 10.1245/s10434-025-17154-7.
6
Long term survival in elderly patients with resectable upper tract urothelial carcinoma: analysis of hospital-based cancer registry data in Japan.可切除性上尿路尿路上皮癌老年患者的长期生存:日本基于医院的癌症登记数据分析
BMC Cancer. 2025 Mar 13;25(1):464. doi: 10.1186/s12885-025-13852-3.
7
Risk Factors Predictive of Contralateral Recurrence of Upper Tract Urothelial Carcinoma Include Chronic Kidney Diseases and Postoperative Initiation of Dialysis.上尿路尿路上皮癌对侧复发的预测危险因素包括慢性肾脏病及术后开始透析。
Cancers (Basel). 2025 Feb 16;17(4):664. doi: 10.3390/cancers17040664.
8
Impact of dialysis on intravesical recurrence and survival outcomes in upper tract urothelial cancer patients undergoing radical nephroureterectomy.透析对接受根治性肾输尿管切除术的上尿路尿路上皮癌患者膀胱内复发及生存结局的影响。
Ren Fail. 2025 Dec;47(1):2458762. doi: 10.1080/0886022X.2025.2458762. Epub 2025 Feb 7.
9
Hematuria in the ER patient: optimizing detection of upper tract urothelial cancer - A pictorial essay.急诊患者的血尿:优化上尿路尿路上皮癌的检测——一篇图文并茂的文章
Emerg Radiol. 2025 Apr;32(2):267-277. doi: 10.1007/s10140-024-02308-z. Epub 2025 Jan 15.
10
Incidence and mortality of upper tract urothelial carcinoma in Korea: A nationwide population-based study conducted from 2002 to 2020.韩国上尿路尿路上皮癌的发病率和死亡率:一项基于全国人口的研究(2002年至2020年)。
Investig Clin Urol. 2025 Jan;66(1):11-17. doi: 10.4111/icu.20240255.